Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

979P - Long-term intracranial safety and efficacy analyses from the phase III CROWN study

Date

10 Sep 2022

Session

Poster session 14

Topics

Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Alessandra Bearz

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

A. Bearz1, E. Felip2, J. Mazieres3, F. de Marinis4, T. Bauer5, A. Polli6, R. Messina7, H. Thurm8, D. Thomaidou9, T.S.K. Mok10, B.J. Solomon11

Author affiliations

  • 1 Medical Oncology, Centro di Riferimento Oncologico - CRO, 33081 - Aviano/IT
  • 2 Medical Oncology Service (lung Cancer Unit)  , Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 3 Pneumonology (incl. Pneumo-oncology), Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, 31059 - Toulouse/FR
  • 4 Thoracic Oncology Department, IEO - Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 5 Medical Oncology, Tennessee Oncology, 37404 - Chattanooga/US
  • 6 Oncology Statistics Department, Pfizer Italy, 20152 - Milan/IT
  • 7 Medical Oncology, Pfizer - Italy, 00188 - Rome/IT
  • 8 Gpd Department, Pfizer Inc - La Jolla Campus - CB10, 92121 - San Diego/US
  • 9 Global Medical Affairs Department, Pfizer Hellas S.A., 154 51 - Neo Psychiko/GR
  • 10 Department Of Clinical Oncology, State Key Laboratory of Translational Oncology and Chinese University of Hong Kong, 999077 - Hong Kong/HK
  • 11 Medical Oncology, Peter MacCallum Cancer Center, 8006 - Melbourne/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 979P

Background

Updated results from the ongoing phase III CROWN study (NCT03052608) confirmed the durable systemic and intracranial (IC) benefit of lorlatinib (LOR), a 3rd generation anaplastic lymphoma kinase (ALK) inhibitor, vs crizotinib (CRIZ) in patients (pts) with treatment-naive ALK-positive non-small cell lung cancer. The 3-year follow up evaluated long-term IC safety and efficacy of LOR (data cutoff 20 September 2021).

Methods

296 pts were randomized 1:1 to oral LOR (100 mg once daily) or CRIZ (250 mg twice daily). CNS adverse events (AEs) were categorized and incidence (onset of new events) of cognitive, mood, speech, and psychotic events calculated within time intervals of LOR treatment. IC time to progression (IC-TTP) was a secondary endpoint, and IC-TTP landmark analysis according to dose reduction ≤16 weeks was performed.

Results

For pts with brain mets at baseline (n=37 LOR/n=39 CRIZ), the HR for IC-TTP for LOR vs CRIZ was 0.10 (95% CI, 0.04–0.27), and for pts without brain mets (n=112/n=108) was 0.02 (95% CI, 0.002–0.14). All-causality CNS AEs occurred in 37 pts (24.8%) treated <6 months, 14 (10.9%) pts between 6 months and 1 year on treatment, 18 (15.4%) pts between 1-2 years, 10 (10.2%) between 2-3 years, and only 2 pts (2.2%) treated for ≥3 years (Table). In total, 103 CNS AEs have been reported. Of these, 61 (59.2%) events were managed without any intervention: 32 (31.1%) resolved spontaneously, 1 (1.0%) improved, 28 (27.2%) did not resolve. Twenty-six events were managed with dose reductions and/or dose interruption with or without concomitant medication. CNS AEs led to permanent discontinuation in 2 pts. Landmark analysis of IC-TTP showed comparable efficacy in pts with or without LOR dose reduction within 16 weeks. CNS AEs observed over time with LOR. Table: 979P

Time interval
≥0 to <6 months (n=149) ≥6 months to <1 year (n=129) ≥1 to <2 years (n=117) ≥2 to <3 years (n=98) ≥3 years (n=92)
Any CNS Adverse Events, n (%) 37 (24.8) 14 (10.9) 18 (15.4) 10 (10.2) 2 (2.2)
CLUSTER Term
Cognitive effects, n (%) 21 (14.1) 7 (5.4) 11 (9.4) 5 (5.1) 1 (1.1)
Mood effects, n (%) 17 (11.4) 5 (3.9) 4 (3.4) 4 (4.1) 0
Speech effects, n (%) 6 (4.0) 2 (1.6) 2 (1.7) 1 (1.0) 1 (1.1)
Psychotic effects, n (%) 4 (2.7) 0 2 (1.7) 2 (2.0) 0

Conclusions

In the 3-year follow up from the CROWN study, the incidence of CNS AEs did not increase over time. Long-term analysis confirmed that CNS AEs remained manageable and LOR dose reductions did not impact IC efficacy.

Clinical trial identification

NCT03052608.

Editorial acknowledgement

Editorial and medical writing support was provided by Ravi Subramanian of ClinicalThinking and was funded by Pfizer.

Legal entity responsible for the study

Pfizer, Inc.

Funding

Pfizer, Inc.

Disclosure

A. Bearz: Financial Interests, Personal, Advisory Role: Boehringer Ingelheim; Financial Interests, Personal, Speaker’s Bureau: Takeda, BMS, Pfizer, AstraZeneca. E. Felip: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, BMS, Eli Lilly, GSK, Janssen, Medical T, MSD, Pfizer, Puma, Sanofi, Merck Serono, Peptomyc, Regeneron, Syneos Health, F. Hoffman La Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Eli Lilly, Medscape, MSD, Peervoice, Pfizer, Springer, Touch Medical, Amgen, F. Hoffman La Roche, Janssen, Medical Trends, Merck Serono; Financial Interests, Personal, Invited Speaker, Independent: Grifols; Financial Interests, Institutional, Invited Speaker: MSD, AstraZeneca, Daiichi Sankyo, Exelixis Inc., Merck KG, Janssen Cilag International NV, GSK, AbbVie Deutschland GmbH & Co KG, Novartis Pharmaceutica SA, Bayer Consumer Care AG, Takeda Pharmaceuticals International, Boehringer Ingelheim, Pfizer S.L.U., Amgen Inc, BMS, Mirati Therapeutics Inc.; Non-Financial Interests, Leadership Role, President: SEOM (Sociedad Espanola de Oncologia Medica); Non-Financial Interests, Member, Member: ESMO, ETOP (European Thoracic Oncology Platform); Non-Financial Interests, Leadership Role, Member: IASLC. J. Mazieres: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, BMS, MSD, Daiichi, Novartis, Amgen; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Pierre Fabre, Takeda, BMS, MSD, Jiangsu Hengruii, Blueprint, Daiichi, Novartis, Amgen, Lilly, Merck; Financial Interests, Institutional, Research Grant: Roche, AstraZeneca, Pierre, Fabre, BMS; Non-Financial Interests, Personal and Institutional, Principal Investigator: Roche, AstraZeneca, Pierre Fabre, Takeda, BMS, MSD, Jiangsu Hengruii, Blueprint, Daiichi, Novartis, Amgen, Sanofi, Pfizer, Merck. T. Bauer: Financial Interests, Personal and Institutional, Invited Speaker: Pfizer, Lilly, Bayer; Financial Interests, Personal and Institutional, Advisory Board: Pfizer, Lilly, Bayer, AZ; Financial Interests, Personal and Institutional, Speaker’s Bureau: Lilly, Bayer, BMS; Financial Interests, Personal and Institutional, Funding: Pfizer; Financial Interests, Personal and Institutional, Principal Investigator: Pfizer, Lilly, Bayer, AZ, BMS; Financial Interests, Personal and Institutional, Research Grant: Lilly, Bayer, AZ, BMS. A. Polli: Financial Interests, Personal, Full or part-time Employment: Pfizer. R. Messina: Financial Interests, Personal and Institutional, Full or part-time Employment: Pfizer. H. Thurm: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. D. Thomaidou: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. T.S.K. Mok: Financial Interests, Personal, Invited Speaker: AbbVie, ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, BeiGene, Boehringer Ingelheim, BMS, Eli Lilly; Financial Interests, Personal, Advisory Board: AbbVie, Acea Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, BeiGene, Boehringer Ingelheim, BMS, Eli Lilly. B.J. Solomon: Financial Interests, Personal and Institutional, Advisory Board: Pfizer, Roche, Novartis, AstraZeneca, Amgen, BMS, Merck, GSK, Takeda, BeiGene, Janssen; Financial Interests, Personal and Institutional, Invited Speaker: Pfizer, Roche, Novartis, AstraZeneca, Amgen, BMS, Merck, GSK, Takeda, BeiGene, Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.